The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study

Decreased trough level of infliximab (TLI) is associated with diminished efficacy in patients with Crohn disease (CD). We examined whether TLI at 14 weeks subsequent to the start of infliximab (IFX) treatment would impact long-term clinical course.Serum IFX levels and antibodies to IFX (ATI) at 14 a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2020-07, Vol.99 (29), p.e21226-e21226
Hauptverfasser:	Ishida, Natsuki, Miyazu, Takahiro, Sugiyama, Tomohiro, Tamura, Satoshi, Kagami, Takuma, Tani, Shinya, Yamade, Mihoko, Iwaizumi, Moriya, Hamaya, Yasushi, Osawa, Satoshi, Furuta, Takahisa, Sugimoto, Ken
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Cohort Studies Crohn Disease - blood Crohn Disease - drug therapy Disease Progression Female Gastrointestinal Agents - pharmacokinetics Gastrointestinal Agents - therapeutic use Humans Infliximab - pharmacokinetics Infliximab - therapeutic use Male Middle Aged Observational Study Prospective Studies Remission Induction Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Decreased trough level of infliximab (TLI) is associated with diminished efficacy in patients with Crohn disease (CD). We examined whether TLI at 14 weeks subsequent to the start of infliximab (IFX) treatment would impact long-term clinical course.Serum IFX levels and antibodies to IFX (ATI) at 14 and 54 weeks after IFX administration were measured in 12 patients with mild to moderate CD. We examined patient background, clinical severity, blood test values, and the relationship between ATI and TLI up to 108 weeks.We compared the group with TLI
ISSN:	0025-7974 1536-5964
DOI:	10.1097/MD.0000000000021226